Joshua Pinto Biography and Net Worth

President of Neumora Therapeutics

Dr. Joshua Pinto currently serves as president of Neumora. He initially joined Neumora as Chief Financial Officer in June 2021 and made significant contributions to the Company, including building its leading neuroscience pipeline through business development efforts and playing a pivotal role in Neumora’s fundraising strategy. In addition to Neumora, Dr. Pinto also serves on the Board of Directors for Metsera, Inc. and earlier in his career was a healthcare investment banker and worked in global external R&D at Eli Lilly. Dr. Pinto holds a B.S. in Business Administration and Biochemistry from Centenary College of Louisiana, an M.B.A. in Finance from McMaster University and a Ph.D. in Neuroscience from McMaster University.

What is Joshua Pinto's net worth?: The estimated net worth of Joshua Pinto is at least $175.45 thousand as of February 18th, 2025. Dr. Pinto owns 76,952 shares of Neumora Therapeutics stock worth more than $175,451 as of December 5th. This net worth estimate does not reflect any other investments that Dr. Pinto may own. Additionally, Dr. Pinto receives an annual salary of $876,640.00 as President at Neumora Therapeutics. Learn More about Joshua Pinto's net worth.
How old is Joshua Pinto?: Dr. Pinto is currently 39 years old. There are 8 older executives and no younger executives at Neumora Therapeutics. The oldest executive at Neumora Therapeutics is Dr. Robert Michael Poole FACP, M.D., Co-Founder & Advisor, who is 67 years old. Learn More on Joshua Pinto's age.
What is Joshua Pinto's salary?: As the President of Neumora Therapeutics, Inc., Dr. Pinto earns $876,640.00 per year. There are 2 executives that earn more than Dr. Pinto. The highest earning executive at Neumora Therapeutics is Mr. Henry O. Gosebruch, President, CEO & Director, who commands a salary of $3,330,000.00 per year. Learn More on Joshua Pinto's salary.
How do I contact Joshua Pinto?: The corporate mailing address for Dr. Pinto and other Neumora Therapeutics executives is , , . Neumora Therapeutics can also be reached via phone at 857-760-0900 and via email at [email protected]. Learn More on Joshua Pinto's contact information.
Has Joshua Pinto been buying or selling shares of Neumora Therapeutics?: Joshua Pinto has not been actively trading shares of Neumora Therapeutics within the last three months. Most recently, Joshua Pinto sold 8,048 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $1.67, for a transaction totalling $13,440.16. Following the completion of the sale, the president now directly owns 76,952 shares of the company's stock, valued at $128,509.84. Learn More on Joshua Pinto's trading history.
Who are Neumora Therapeutics' active insiders?: Neumora Therapeutics' insider roster includes Kristina Burow (Director), and Joshua Pinto (President). Learn More on Neumora Therapeutics' active insiders.
Are insiders buying or selling shares of Neumora Therapeutics?: In the last twelve months, Neumora Therapeutics insiders bought shares 2 times. They purchased a total of 3,831,400 shares worth more than $9,999,954.00. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 124,729 shares worth more than $324,187.02. The most recent insider tranaction occured on November, 11th when insider Daljit Singh Aurora sold 114,703 shares worth more than $307,404.04. Insiders at Neumora Therapeutics own 26.8% of the company. Learn More about insider trades at Neumora Therapeutics.
Information on this page was last updated on 11/11/2025.

Joshua Pinto Insider Trading History at Neumora Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2025	Sell	8,048	$1.67	$13,440.16	76,952
8/26/2024	Sell	31,642	$11.78	$372,742.76	154,658
8/22/2024	Sell	28,496	$11.63	$331,408.48	210,469

Joshua Pinto Buying and Selling Activity at Neumora Therapeutics

Neumora Therapeutics Company Overview

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $2.28

$2.22

$2.36

50 Day Range

MA: $2.27

$1.71

$3.02

2 Week Range

Now: $2.28

$0.61

$11.57

Volume

1,058,660 shs

Average Volume

1,186,396 shs

Market Capitalization

$380.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.12

Joshua Pinto Biography and Net Worth

What is Joshua Pinto's net worth?

How old is Joshua Pinto?

What is Joshua Pinto's salary?

How do I contact Joshua Pinto?

Has Joshua Pinto been buying or selling shares of Neumora Therapeutics?

Who are Neumora Therapeutics' active insiders?

Are insiders buying or selling shares of Neumora Therapeutics?